International AIDS Vaccine Initiative Agreement –Targeted Genetics Corporation and the International AIDS Vaccine Initiative (IAVI) entered into an industrial collaboration in 2000, to undergo the development of a vaccine to treat HIV/AIDS. In 2006, we replaced that agreement with a new collaboration and license agreement. Under the terms of the collaboration, IAVI funds development of a vaccine to protect against the progression of HIV infection to AIDS for use in the developing world. Under this agreement, Targeted Genetics has retained exclusive rights to commercialize any product that results from the collaboration in developed countries and rights to use the findings from the program for the development of other vaccines.
About IAVI –The International AIDS Vaccine Initiative (www.iavi.org) is a global nonprofit scientific organization working to speed the search for a vaccine to prevent HIV/AIDS. IAVI sponsors research partnerships to develop and test promising vaccine candidates. IAVI’s major financial supporters include the Bill & Melinda Gates Foundation; the Rockefeller, Sloan and Starr foundations; the World Bank; BD; the European Commission; and eight national governments that provide support through the Canada Fund for Africa Secretariat of the Canadian International Development Agency, the UK Department for International Development, the US Agency for International Development, the Netherlands Ministry of Foreign Affairs, Development Cooperation Ireland, the Ministry of Foreign Affairs of Denmark, the Norwegian Royal Ministry of Foreign Affairs and the Swedish International Development Cooperation.
Celladon Corporation – In December 2004, Targeted Genetics established a collaboration with Celladon Corporation focused on the development of AAV-based drugs for the treatment of congestive heart failure. In connection with the formation of this collaboration, Enterprise Partners and Venrock Associates purchased shares of our common stock for net proceeds of $6.0 million.
About Celladon – Celladon, Inc., a privately held company based in La Jolla, California, was founded by Dr. Kenneth R. Chien M.D., Ph.D. and Dr. Roger J. Hajjar, M.D. The company is focused on developing novel molecular therapies for congestive heart failure. The company’s first product targets the treatment of congestive heart failure by enhancing calcium cycling in the heart through a gene based therapy. Founding investors include Enterprise Partners Venture Capital and Venrock Associates. For more information about Celladon, visit its website at www.celladon.net.
MULTIPLE ACADEMIC PARTNERS
Targeted Genetics also maintains strong relationships with various academic institutions. Our capabilities enable us to license technologies that are interesting and applicable to our research, product development and manufacturing.
|
